Companies · Pharma

CHARM Therapeutics Inc.

LONDON · Pharma · refined from filed group “Other

Diligence memoA one-page analyst read on CHARM Therapeutics Inc. — recommendation, valuation, rhythm, risks.
$87.0M
Total raised · real
4
Rounds
0.9×
Latest step-up
Top 11%
Sector rank · raised
Series B
Latest stage · inferred · Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

CHARM Therapeutics Inc. looks fair against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.80× the median modeled value of Series B Pharma companies in 2025–2027 (8 peers) — value vs value, same stage and era.
  • Within the normal band (80% of peer median) for its niche.
Active
  • Last raise 10 mo ago; this sector typically re-raises about every 16 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharma

CHARM Therapeutics Inc. is one of 310 Pharma companies tracked from LONDON. By capital raised it ranks among the largest (ahead of 90% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
20
Investors (latest)
2021
Year incorporated
2025-08-19
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries A · 2021-10-14 Raised $13M (real) Modeled valuation $220M (est)$13M$220MSeries A2021Series B · 2022-04-18 Raised $37M (real) Modeled valuation $619M (est)$37M$619MSeries B2022Series B · 2023-04-06 Raised $20M (real) Modeled valuation $229M (est)$20M$229MSeries B2023Series B · 2025-08-19 Raised $17M (real) Modeled valuation $77M (est)$17M$77MSeries B2025+$37M+$20M+$17MCumulative $87M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$12.6M · 2021
Series B$37.0M · 2022
Series B extension$20.0M · 2023
Series B extension$17.3M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$77.3M
Base estimate est.
$36.3M
Conservative case
$111.4M
Upside case
$96.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series A · modeled $220.0M · 2021-10-142021Series B · modeled $618.9M · 2022-04-18Series B · modeled $228.8M · 2023-04-06Series B · modeled $77.3M · 2025-08-192025
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
57%
Survival probability
38% low · 70% high
1.49×/yr
Annual markup
1.80×/yr upside case
0.9 yr
Elapsed time used
0.9 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
15 mo
Avg between rounds
$22.6M/yr
Capital velocity
4.7 yr
On record since
2021
First round
4
Rounds on file
How it compares to the market

Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 14× above median
This company$87.0M
Sector median$6.4M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.9× of median
This company$17.3M
Sector median$19.0M
Modeled value — vs sector median (estimate, all stages) 1.2× above median
This company$77.3M
Sector median$62.5M

Raised more than 90% of sector peers (real $). Modeled value above 62% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #7 of 8.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)Juvena Therapeutics, Inc. · Series B Raised $34.8M · modeled $144.4M (est)Alessa Therapeutics, Inc. · Series B Raised $31.6M · modeled $129.6M (est)Amani Therapeutics, Inc. · Series B Raised $31.1M · modeled $125.2M (est)Shenandoah Therapeutics Inc. · Series B Raised $21.5M · modeled $108.2M (est)Atlas Oncology Holdings Inc. · Series B Raised $23.0M · modeled $85.1M (est)TwoStep Therapeutics, Inc. · Series B Raised $27.6M · modeled $80.9M (est)Nuo Therapeutics, Inc. · Series B Raised $46.3M · modeled $3.6M (est)CHARM Therapeutics Inc. (this company) Raised $87.0M · modeled $77.3M (est)CHARM Therapeutics Inc.
CompanyStageRaised · realValue · estvs peer med.
Juvena Therapeutics, Inc.Series B$34.8M$144.4M1.49×
Alessa Therapeutics, Inc.Series B$31.6M$129.6M1.34×
Amani Therapeutics, Inc.Series B$31.1M$125.2M1.30×
Shenandoah Therapeutics Inc.Series B$21.5M$108.2M1.12×
Atlas Oncology Holdings Inc.Series B$23.0M$85.1M0.88×
TwoStep Therapeutics, Inc.Series B$27.6M$80.9M0.84×
CHARM Therapeutics Inc. this companySeries B$87.0M$77.3M0.80×
Nuo Therapeutics, Inc.Series B$46.3M$3.6M0.04×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$12.6M2021-10-14$57.5M$220.0M90%
Series B$37.0M2022-04-18$205.6M$618.9M90%
Series B$20.0M2023-04-06$111.4M$228.8M90%
Series B$17.3M2025-08-19$96.1M$77.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$12.6M2021-10-14
    • First recorded raise — entered as Series A.
    • 8 investors on this round.
  2. Series B$37.0M2022-04-18
    • Came back fast: 6 mo vs the ~16 mo sector norm.
    • Round 2.9× larger than the prior — scaling up.
    • 18 investors on this round.
  3. Series B$20.0M2023-04-06
    • Raised 12 mo later, in step with the ~16 mo sector norm.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  4. Series B$17.3M2025-08-19
    • Raised again after 28 mo — slower than the ~16 mo sector norm.
    • Round roughly the size of the prior one.
    • 20 investors on this round.
Intelligence
2026 ~Q4
Modeled next raise · ~15mo cadence
$17.3M
Modeled next size est.range $17.3M$27.7M
0.9×
Last step-up
$22.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Rishi Gupta11 other2025-08
Briggs Morrison7 other2025-08
Gary Glick6 other2025-08
Kim Blackwell2 other2025-08
Nihal Sinha1 other2025-08
Gary Singh Glick2022-04
Lakshyaditya Singh Aithani2021-10
Mahesh Kudari2025-08
Matthew McAviney2025-08
Muzammil Singh Mansuri2022-04
Nihal Singh Sinha2022-04
Rishi Singh Gupta2022-04
Registry & provenance

CHARM Therapeutics Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1889676
SEC CIK
2021
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
SPR Therapeutics, Inc.PharmaSeries B$81.6M$211.8Msame sector · same stage
Rescale, Inc.PharmaSeries B$58.2M$996.3Msame sector · same stage
Oncology Analytics, Inc.PharmaSeries B$53.5M$850.1Msame sector · same stage
Crossbow Therapeutics, Inc.BiotechnologySeries B$67.8M$128.2Mnetwork1 shared operator · same stage
Nuo Therapeutics, Inc.PharmaSeries B$46.3M$3.6Msame sector · same stage
EIP Pharma, Inc.PharmaSeries B$44.1M$8.3Msame sector · same stage
Multiply Labs, Inc.PharmaSeries B$41.2M$126.2Msame sector · same stage
Small Pharma Financing Inc.PharmaSeries B$35.1M$909.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Bold Therapeutics Inc.PharmaSeries A$169.6M84%
Compass Therapeutics, Inc.PharmaSeries D+$2.1B82%
Notch Therapeutics, Inc.PharmaSeries B$113.9M82%
Circle Pharma, Inc.PharmaSeries C$811.4M81%
Luxvitae Therapeutics Inc.PharmaSeries A$36.7M81%
CHARM Solutions US Holding, Inc.OtherSeed$24.9M81%
Constance Therapeutics, Inc.PharmaSeries A$131.6M80%
Violet Therapeutics, Inc.PharmaSeries A$65.7M80%
Frequently asked
How much funding has CHARM Therapeutics Inc. raised?
CHARM Therapeutics Inc. has raised approximately $87.0M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is CHARM Therapeutics Inc.'s estimated valuation?
Provath's modeled valuation for CHARM Therapeutics Inc. is approximately $77.3M (modeled range $36.3M–$111.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is CHARM Therapeutics Inc. at?
CHARM Therapeutics Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Tue Aug 19.
What does CHARM Therapeutics Inc. do and where is it based?
CHARM Therapeutics Inc. operates in the Pharma sector, based in LONDON.
Explore related

See where CHARM Therapeutics Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at CHARM Therapeutics Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.